Yuhan Corporation (000100) Fair Value & Analysis

Healthcare · KR · Market cap 5.8T KRW

Analysis

Yuhan Corporation (000100) currently trades at 73,400 KRW, while our model-based Fair Value estimate is 44,818 KRW — implying the stock looks roughly 38.9% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Yuhan Corporation operates as a pharmaceutical company in South Korea and internationally. It offers manufacturing services, such as custom manufacturing; process research and development of active pharmaceutical products (APIs) and intermediates; kilo and pilot-scale production of APIs and intermediates; commercial production of APIs and intermediates; production of chemical specialties; and analytical method development and regulatory support. The company also provides APIs and intermediates, including antibiotic, anti-thrombotic, anti-hyperlipidemics, and anti-hypertensive; and custom sy…

Open the full interactive analysis →

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.